



US008383662B2

(12) **United States Patent**
Sun et al.

(10) **Patent No.:** **US 8,383,662 B2**
(45) **Date of Patent:** **Feb. 26, 2013**

(54) **BICYCLIC HETEROARYL COMPOUNDS**

(75) Inventors: **Chung-Ming Sun**, Rancho Cucamonga, CA (US); **Min-Liang Kuo**, Taipei (TW); **Yufeng Jane Tseng**, Taipei (TW)

(73) Assignees: **National Chiao Tung University**, Hsinchu (TW); **National Taiwan University**, Taipei (TW)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/896,244**

(22) Filed: **Oct. 1, 2010**

(65) **Prior Publication Data**

US 2011/0082143 A1 Apr. 7, 2011

Related U.S. Application Data

(63) Continuation-in-part of application No. 11/949,070, filed on Dec. 3, 2007, now Pat. No. 7,825,261.

(60) Provisional application No. 60/873,041, filed on Dec. 5, 2006.

(51) **Int. Cl.**

A61K 31/416 (2006.01)

A61K 31/4184 (2006.01)

C07D 235/04 (2006.01)

C07D 209/02 (2006.01)

(52) **U.S. Cl.** **514/394**; 514/405; 548/305.1; 548/361.1

(58) **Field of Classification Search** 514/394, 514/405; 548/305, 361.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,511,145 B2 * 3/2009 Schmitz et al. 546/167
2005/0187390 A1 * 8/2005 Schmitz et al. 544/310

OTHER PUBLICATIONS

STN-12896244-preliminary-02202012 (2012).*
Chang et al., Journal of Combinatorial Chemistry, (2008), vol. 10, p. 466-474.*

Yeh et al., Combinatorial Chemistry and High Throughput Screening (2004), 7(3), p. 251-255.*


* cited by examiner

Primary Examiner — Yong Chu

(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

Bicyclic heteroaryl compounds of formula (I) shown below are disclosed. Each variable in formula (I) is defined in the specification. Also disclosed is treatment of cancer with these compounds.



8 Claims, 5 Drawing Sheets




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5B




Figure 5A

1

BICYCLIC HETEROARYL COMPOUNDS

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part and claims priority to U.S. patent application Ser. No. 11/949,070, filed Dec. 3, 2007 now U.S. Pat. No. 7,825,261, which in turn claims priority to U.S. Provisional Application Ser. No. 60/873,041, filed Dec. 5, 2006. The contents of these two applications are incorporated herein in its entirety.


BACKGROUND

Lymphangiogenesis is the formation of lymphatic vessels from pre-existing lymphatic vessels. It plays an important role in promoting neoplasm metastasis. It has been found that vascular endothelial growth factor receptor-3 (VEGFR-3) mediates lymphangiogenesis in response to its two ligands, VEGF-C and VEGF-D. Thus, it is desirable to develop novel drugs that inhibit the VEGFR-3/ligand signaling pathway for cancer treatment.

SUMMARY

This invention is based on the discovery that certain bicyclic heteroaryl compounds are effective in reducing metastasis and treating cancer by inhibiting VEGFR-3 activities.

In one aspect, this invention features bicyclic heteroaryl compounds of formula (I):



In this formula, each of X_1 , X_2 , and X_3 , independently, is C or N, and at least two of X_1 , X_2 , and X_3 are each N; each of R_1 and R_3 , independently, is deleted, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, CN, NO_2 , OR_a , $COOR_a$, $OC(O)R_a$, $C(O)R_a$, $C(O)NR_dR_e$, $C(O)N(R_d)N(R_b)C(O)R_f$, NR_dR_e , $N(R_f)SO_2NR_dR_e$, $SO_2NR_dR_e$, or SR_a , in which each of R_a , R_b , and R_e , independently, is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R_a and R_b together with the nitrogen atom to which they are attached form heterocycloalkyl or heteroaryl; R_2 is heterocycloalkenyl, aryl, or heteroaryl; each of R_4 , R_5 , R_6 , and R_7 , independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, CN, NO_2 , OR_d , $COOR_d$, $OC(O)R_d$, $C(O)R_d$, $C(O)NR_dR_e$, $C(O)N(R_d)N(R_e)C(O)R_f$, NR_dR_e , $N(R_f)SO_2NR_dR_e$, $SO_2NR_dR_e$, or SR_d , in which each of R_d , R_e , and R_f , independently, is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R_d and R_e together with the nitrogen atom to which they are attached form heterocycloalkyl or heteroaryl.


Referring to formula (I), a subset of the bicyclic heteroaryl compounds described above are those in which each of X_1 and X_3 is N and X_2 is C. In these compounds, R_2 can be heterocycloalkenyl or heteroaryl; R_1 can be alkyl or cycloalkyl; each of R_4 , R_5 , R_6 , and R_7 , independently, can be

2

H, C_1 - C_{10} alkyl, NR_dR_e , $COOR_d$, $C(O)NR_dR_e$, $C(O)N(R_d)N(R_e)C(O)R_f$ or heteroaryl; or R_5 can be $COOR_d$ and each of R_4 , R_6 , and R_7 , independently, can be H.

Another subset of the bicyclic heteroaryl compounds of formula (I) described above are those in which each of X_1 and X_3 is N, X_2 is C, and R_2 is benzimidazol-4-yl, dihydrobenzimidazol-4-yl, indazol-6-yl, or phenyl (e.g., phenyl substituted with amino, amido, or thioureido). In these compounds, R_1 can be alkyl or cycloalkyl; each of R_4 , R_5 , R_6 , and R_7 , independently, can be H, C_1 - C_{10} alkyl, NR_dR_e , $COOR_d$, $C(O)NR_dR_e$, $C(O)N(R_d)N(R_e)C(O)R_f$ or heteroaryl; or R_5 can be $COOR_d$ and each of R_4 , R_6 , and R_7 , independently can be H.

Still another subset of the bicyclic heteroaryl compounds of formula (I) described above are those in which each of X_1 and X_3 is N, X_2 is C, and R_2 is



in which Y is O, S, Se, or NR_g , R_g being H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R_8 is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, SR_h , SeR_h , or NR_hR_i , each of R_h and R_i independently being H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In these compounds, Y can be NR_g and R_8 can be SR_h , or SeR_h ; or R_8 can be NR_g and Y can be SR_h , or SeR_h ; R_1 can be alkyl or cycloalkyl; each of R_4 , R_5 , R_6 , and R_7 , independently, can be H, C_1 - C_{10} alkyl, NR_dR_e , $COOR_d$, $C(O)NR_dR_e$, $C(O)N(R_d)N(R_e)C(O)R_f$ or heteroaryl; or R_5 can be $COOR_d$ and each of R_4 , R_6 , and R_7 , independently can be H.

The term "alkyl" refers to a straight or branched monovalent hydrocarbon containing, unless otherwise stated, 1-20 carbon atoms (e.g., C_1 - C_{10} or C_1 - C_4). Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl. The term "alkenyl" refers to a straight or branched monovalent hydrocarbon containing 2-20 carbon atoms (e.g., C_2 - C_{10} or C_2 - C_4) and one or more double bonds. Examples of alkenyl include, but are not limited to, ethenyl, propenyl, propenylene, allyl, and 1,4-butadienyl. The term "alkynyl" refers to a straight or branched monovalent hydrocarbon containing 2-20 carbon atoms (e.g., C_2 - C_{10}) and one or more triple bonds. Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 1- and 2-butynyl, and 1-methyl-2-butynyl. The term "alkoxy" refers to an $-O$ -alkyl radical. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy. The term "acyloxy" refers to an $-O-C(O)-R$ radical in which R can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. The term "amino" refers to NH_2 , alkylamino, or arylamino. The term "alkylamino" refers to an $-N(R)$ -alkyl radical in which R can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. The terms "amido" and "carbamido" refer to $-NRC(O)R'$ and $-C(O)NRR'$ radicals respectively, in which each of R and R',

independently, can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.

The term "cycloalkyl" refers to a monovalent saturated hydrocarbon ring system having 3 to 30 carbon atoms (e.g., C₃-C₁₂). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1,4-cyclohexylene, cycloheptyl, cyclooctyl, and adamantyl. The term "cycloalkenyl" refers to a monovalent non-aromatic hydrocarbon ring system having 3 to 30 carbons (e.g., C₃-C₁₂) and one or more double bonds. Examples include cyclopentenyl, cyclohexenyl, fluorenyl, and cycloheptenyl. The term "heterocycloalkyl" refers to a monovalent nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having one or more heteroatoms (such as O, N, S, or Se). Examples of heterocycloalkyl groups include, but are not limited to, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, 4-tetrahydropyranyl, and tetrahydrofuranyl. The term "heterocycloalkenyl" refers to a monovalent nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having one or more heteroatoms (such as O, N, S, or Se) and one or more double bonds. Examples of heterocycloalkenyl groups include, but are not limited to, pyranyl, dihydrobenzimidazolyl and 1,3-dihydrospiro[benzo[d]imidazol-2,1'-cyclopentane]-4-yl.

The term "aryl" refers to a monovalent 6-carbon monocyclic, 10-carbon bicyclic, 14-carbon tricyclic aromatic ring system. Examples of aryl groups include, but are not limited to, phenyl ("ph"), naphthyl, pyrenyl, anthryl, and phenanthryl. The term "aryloxy" refers to an —O-aryl. The term "arylamino" refers to an —N(R)-aryl in which R can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. The term "heteroaryl" refers to a monovalent aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having one or more heteroatoms (such as O, N, S, or Se). Examples of heteroaryl groups include pyridyl, pyrrolyl, furyl, imidazolyl, indazolyl, benzimidazolyl, pyrimidinyl, thienyl, oxazolyl, quinolyl, isoquinolyl, quinazolinyl, indolyl, and thiazolyl.

Alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, amino, aryl, and heteroaryl mentioned above include both substituted and unsubstituted moieties. Possible substituents on amino, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, and heteroaryl include, but are not limited to, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₂₀ cycloalkyl, C₃-C₂₀ cycloalkenyl, C₁-C₂₀ heterocycloalkyl, C₁-C₂₀ heterocycloalkenyl, C₁-C₁₀ alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C₁-C₁₀ alkylamino, arylamino, C₁-C₁₀ alkylimino, arylimino, C₁-C₁₀ alkylsulfonimino, arylsulfonimino, hydroxy, halo, oxo (O=), thioxo (S=), thio, silyl, C₁-C₁₀ alkylthio, arylthio, C₁-C₁₀ alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino, mercapto, amido, thioureido, thiocyanato, sulfonamido, guanidine, ureido, cyano, nitro, nitroso, azido, acyl, thioacyl, acyloxy, carbamido, carbamyl (—C(O)NH₂), carboxyl (—COOH), and carboxylic ester. On the other hand, possible substituents on alkyl, alkenyl, alkylenyl, alkenylene, heteroalkylene, heteroalkenylene, or alkynyl include all of the above-recited substituents except C₁-C₁₀ alkyl. Cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl can also be fused with each other by sharing one or more atoms (e.g., to form a spiro compound).

In another aspect, this invention features a method for treating cancer. The method includes administering to a sub-

ject in need thereof an effective amount of one or more bicyclic heteroaryl compounds of formula (I) shown above. An example of cancer that can be treated by the bicyclic heteroaryl compounds of this invention is lung cancer. The term "treating" or "treatment" refers to administering one or more bicyclic heteroaryl compounds to a subject, who has an above-described disease, a symptom of such a disease, or a predisposition toward such a disease, with the purpose to confer a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the above-described disease, the symptom of it, or the predisposition toward it.

In addition, this invention encompasses a pharmaceutical composition that contains at least one of the above-mentioned bicyclic heteroaryl compounds and a pharmaceutically acceptable carrier.

The bicyclic heteroaryl compounds described above include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on a bicyclic heteroaryl compound. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate, salicylate, naphthalenesulfonate, glutamate, glucuronate, lactate, glutarate succinate, and maleate. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a bicyclic heteroaryl compound. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. The bicyclic heteroaryl compounds also include those salts containing quaternary nitrogen atoms. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active bicyclic heteroaryl compounds. A solvate refers to a complex formed between an active bicyclic heteroaryl compound and a pharmaceutically acceptable solvent. Examples of pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.

Also within the scope of this invention is a composition containing one or more of the bicyclic heteroaryl compounds described above for use in treating cancer, and the use of such a composition for the manufacture of a medicament for the just-mentioned treatment.

The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the following drawing, detailed description of embodiments, and also from the appending claims.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates the efficacy of certain compounds of this invention in inhibiting tumor growth in mice.

FIG. 2 illustrates the efficacy of certain compounds of this invention in inhibiting spontaneous metastasis in mice. N.D.: not detected.

FIG. 3 illustrates the effect of certain compounds of this invention on reducing tumor recurrence in mice. N.D.: not detected.


FIG. 4 illustrates the effect of certain compounds of this invention on survival rates of mice.

FIGS. 5A and 5B illustrate the inhibitory effect of Compound 56 on tumor self-seeding.

DETAILED DESCRIPTION


Shown below are 185 exemplary compounds of this invention:

5




6


Compound 1




Compound 2




Compound 3




Compound 4




Compound 5




Compound 6




Compound 7




Compound 8




Compound 9



Compound 10



Compound 11




Compound 12


7

8


-continued




Compound 13




Compound 14




Compound 15




Compound 16




Compound 17




Compound 18




Compound 19




Compound 20




Compound 21



Compound 22



Compound 23





Compound 24

-continued



Compound 25

Compound 26





Compound 27

Compound 28





Compound 29

Compound 30





Compound 31

Compound 32




Compound 33

Compound 34




11



12


-continued

Compound 35




Compound 36


Compound 37




Compound 38




Compound 39




Compound 40




Compound 41




Compound 42



Compound 43



Compound 44




13

14



-continued

Compound 45





Compound 46

Compound 47





Compound 48

Compound 49





Compound 50

Compound 51




Compound 52

Compound 53




15




-continued
Compound 54

16




Compound 55


Compound 56




Compound 57




Compound 58



Compound 59




17




-continued
Compound 60

18




Compound 61


Compound 62




Compound 63




Compound 64



Compound 65



19




20

-continued



Compound 66

Compound 67





Compound 68

Compound 69





Compound 70

Compound 71



Compound 72

Compound 73





21

22

-continued



Compound 74

Compound 75





Compound 76

Compound 77





Compound 78

Compound 79




Compound 80

Compound 81




23




-continued
Compound 82

24




Compound 83


Compound 84




Compound 85




Compound 86




Compound 87



Compound 88



Compound 89





25

26

-continued



Compound 90

Compound 91





Compound 92

Compound 93




Compound 94


Compound 95



27




28




-continued
Compound 96

Compound 97


Compound 98




Compound 99




Compound 100




Compound 101



29



30





-continued

Compound 102

Compound 103



Compound 104

Compound 105



Compound 106

Compound 107





31

32



-continued
Compound 108

Compound 109





Compound 110

Compound 111




Compound 112

Compound 113




33



34


-continued

Compound 114




Compound 115


Compound 116




Compound 117



Compound 118



Compound 119





35

36



-continued
Compound 120

Compound 121





Compound 122

Compound 123



Compound 124

Compound 125





37

38

-continued



Compound 126

Compound 127





Compound 128

Compound 129





Compound 130

Compound 131



Compound 132

Compound 133





39

40

-continued



Compound 134

Compound 135





Compound 136

Compound 137





Compound 138

Compound 139



Compound 140

Compound 141





41

42

-continued



Compound 142

Compound 143





Compound 144

Compound 145




Compound 146

Compound 147




43



44


-continued

Compound 148




Compound 149


Compound 150




Compound 151




Compound 152



Compound 153




45



46


-continued

Compound 154




Compound 155


Compound 156




Compound 157



Compound 158



Compound 159





47

48



-continued
Compound 160

Compound 161





Compound 162

Compound 163




Compound 164


Compound 165



49



50




-continued


Compound 166

Compound 167


Compound 168




Compound 169




Compound 170



Compound 171




51



Compound 172


52




Compound 173

-continued


Compound 174




Compound 175




Compound 176



Compound 177




53




-continued
Compound 178


54




Compound 179




Compound 180



Compound 181



Compound 182



Compound 183



55

56

-continued



Compound 184

Compound 185





Compound 186

Compound 187





Compound 188

Compound 189




Compound 190

Compound 191




57




-continued
Compound 192


58




Compound 193




Compound 194



Compound 195




Compound 196




Compound 197

59




-continued
Compound 198

60




Compound 199


Compound 200




Compound 201




Compound 202




Compound 203




Compound 204



Compound 205




61




-continued
Compound 206

62




Compound 207


Compound 208




Compound 209




Compound 210




Compound 211



Compound 212



Compound 213





63

64

-continued



Compound 214

Compound 215





Compound 216

Compound 217




Compound 218

Compound 219




65




-continued
Compound 220

66




Compound 221


Compound 222




Compound 223




Compound 224



Compound 225




67




-continued
Compound 226

68




Compound 227


Compound 228




Compound 229




Compound 230



Compound 231




69




-continued
Compound 232

70




Compound 233


Compound 234




Compound 235




Compound 236



Compound 237




71




-continued
Compound 238


72




Compound 239




Compound 240



Compound 241



Compound 242



Compound 243



73

74

-continued



Compound 244

Compound 245





Compound 246

Compound 247




Compound 248

Compound 249




75




-continued
Compound 250

76




Compound 251


Compound 252



Compound 253




77




-continued
Compound 254

78




Compound 255

Compound 256



Compound 257





79

80

-continued



Compound 258

Compound 259




Compound 260

Compound 261




81




-continued
Compound 262

82




Compound 263


Compound 264



Compound 265




83




-continued
Compound 266

84




Compound 267

Compound 268



Compound 269





85

86



-continued
Compound 270

Compound 271




Compound 272

Compound 273




87




-continued
Compound 274


88




Compound 275




Compound 276



Compound 277




Compound 278




Compound 279

89




90


-continued
Compound 280




Compound 281




Compound 282



Compound 283




Compound 284




Compound 285

91




-continued
Compound 286

92




Compound 287


Compound 288




Compound 289




Compound 290



Compound 291




93




94


-continued
Compound 292




Compound 293




Compound 294



Compound 295




Compound 296



Compound 297


95




96

-continued


Compound 298




Compound 299




Compound 300



Compound 301




Compound 302




Compound 303

97




98



-continued


Compound 304

Compound 305





Compound 306

Compound 307




Compound 308


Compound 309



99




100


-continued
Compound 310

Compound 311


Compound 312




Compound 313



Compound 314




Compound 315



The bicyclic heteroaryl compounds described above can be prepared by methods well known in the art. Examples 1-186 below provide detailed descriptions of how Compounds 1-186 were actually prepared.

Scheme I shown below illustrates a typical synthetic route for synthesizing certain exemplary bicyclic heteroaryl compounds. R_2 and R_3 in this scheme can be those described in the Summary section above.

101




R = halo

Specifically, as shown in Scheme I above, a substituted benzene containing a nitro group and a halo group can first react with a primary amine compound to form a secondary

102


amine compound. This compound can then undergo a ring closure reaction between the nitro group and the secondary amino group to form a bicyclic heteroaryl compound of this invention.



5 Scheme II below illustrates a synthetic route for synthesizing bicyclic heteroaryl compounds in which X_1 and X_3 is N, X_2 is C, and R_2 is



R_1 and R_4 though R_8 in this scheme can be those described in the Summary section above. R_9 can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.

Scheme II





A bicyclic heteroaryl compound synthesized above can be purified by a suitable method such as column chromatography, high-pressure liquid chromatography, or recrystallization.

Other bicyclic heteroaryl compounds can be prepared using other suitable starting materials through the above synthetic routes and others known in the art such as those described in Chen et al., *J. Comb. Chem.*, 2009 (11), 1038-1046. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the bicyclic heteroaryl compounds. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable bicyclic heteroaryl compounds are known in the art and include, for example, those described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic Synthesis*, 2nd Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995) and subsequent editions thereof.

The bicyclic heteroaryl compounds mentioned herein may contain a non-aromatic double bond and one or more asymmetric centers. Thus, they can occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans-isomeric forms. All such isomeric forms are contemplated.

Also within the scope of this invention is a pharmaceutical composition containing at least one bicyclic heteroaryl compound described above and a pharmaceutical acceptable carrier. Further, this invention covers a method of administering an effective amount of one or more of the bicyclic heteroaryl compounds to a patient having cancer. "An effective amount" refers to the amount of an active bicyclic heteroaryl compound that is required to confer a therapeutic effect on the treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment. For example, a daily dose of 5 mg/kg of compound 1 can be used to reduce metastasis and a daily dose of 50 mg/kg can be used to inhibit tumor growth.

To practice the method of the present invention, a composition having one or more bicyclic heteroaryl compounds can be administered parenterally, orally, nasally, rectally, topically, or buccally. The term "parenteral" as used herein refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal,

intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique.

A sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides). Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation.

A composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions. In the case of tablets, commonly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.

A nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation. For example, such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

A composition having one or more active bicyclic heteroaryl compounds can also be administered in the form of suppositories for rectal administration.

The carrier in the pharmaceutical composition must be "acceptable" in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of an active bicyclic heteroaryl compound. Examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow #10.


105

The bicyclic heteroaryl compounds described above can be preliminarily screened for their efficacy in treating above-described diseases by in vitro and in vivo assays (see Examples 186 and 187 below) and then confirmed by clinic trials. Other methods will also be apparent to those of ordinary skill in the art.

The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.

EXAMPLE 1

Preparation of Compound 1: methyl 2-(3,3-diphenylpropyl)-2H-indazole-6-carboxylate



A solution of dicyclohexylcarbodiimide (DCC, 0.95 g, 4.61 mmol, 1.2 equiv) in 10 mL of dichloromethane (DCM) was added dropwise to a stirred mixture of 4-bromomethyl-3-nitro-benzoic acid 1 (1.0 g, 3.84 mmol, 1.0 equiv) and 4-dimethylaminomethyl pyridine (DMAP) (0.020 g, 0.19 mmol, 0.05 equiv) in 10 mL of dichloromethane-methanol (10%) at room temperature. The mixture was stirred for 6 hours to obtain 4-bromomethyl-3-nitro-benzoic acid methyl

106

ester 2. Dicyclohexyl urea (DCU) thus obtained was removed by filtration and the solvent in the filtered solution was removed under vacuum. The residue was purified by column chromatography using hexane-ethyl acetate (15%) as an eluant to give ester 2 as a light yellow oil.

To a solution of ester 2 (0.91 g, 3.32 mmol, 1.0 equiv) in 10 mL of dichloromethane was added dropwise 3,3-diphenylpropylamine (1.40 g, 6.64 mmol, 2.0 equiv). The mixture was stirred at room temperature for 8 hours. After the amine salt thus obtained was removed by filtration, the solvent in the filtered solution was removed under vacuum to give crude 4-[(3,3-diphenyl-propylamino)-methyl]-3-nitro-benzoic acid methyl ester 3. The crude product was purified by column chromatography using hexane-ethyl acetate (25%) to give ester 3 as a light brown oil.

4-[(3,3-diphenyl-propylamino)-methyl]-3-nitro-benzoic acid methyl ester 3 (0.81 g, 3.21 mmol) was dissolved in 10 mL of methanol and treated with ammonium formate (1.26 g, 20.02 mmol, 10 equiv) and palladium on carbon (162 mg, 20%). The mixture was stirred for 1 day at room temperature. After the mixture was then filtered through a small plug of Celite and washed with dichloromethane, the solvent was removed under vacuum to give a crude product. The crude product was purified by column chromatography using hexane-ethyl acetate (25%) to give compound 1, 2-(3,3-diphenyl-propyl)-2H-indazole-6-carboxylic acid methyl ester, as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 8.53 (s, 1H), 7.82 (s, 1H), 7.75-7.72 (dd, J=8.7, 1.2 Hz, 1H), 7.69-7.66 (dd, J=8.7, 0.5 Hz, 1H), 7.35-7.20 (m, 10H), 4.41 (t, J=6.9 Hz, 2H), 3.97 (s, 3H), 3.88 (t, J=7.9 Hz, 1H), 2.87-2.80 (q, J=7.2 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 167.56, 148.13, 143.25, 128.68, 127.71, 126.61, 123.65, 123.27, 121.28, 121.18, 120.07, 52.36, 52.13, 48.12, 35.94; IR (cm⁻¹, neat): 3236, 2948, 1713, 1601, 1443, 1269.

MS (EI): m/z 370 (M⁺). Exact mass calculated for C₂₄H₂₂N₂O₂: m/z 370.1681 Found 370.1681.

EXAMPLES 2-55

Preparation of Compounds 2-55

Compounds 2-55 were prepared in a manner similar to that described in Example 1.

EXAMPLES 56-186

Preparation of Compounds 56-186

Compounds 56-186 were prepared in a manner similar to that described in Example or that described in Chen et al., *J. Comb. Chem.*, 2009 (11), 1038-1046.

EXAMPLE 187

KIRA-ELISA Assay

This assay was performed in two microtiter plates. The first plate was used to culture an adherent cell line expressing the VEGF receptor 3 and to stimulate the receptor with a test compound. The second plate was used to capture the solubilized membrane receptor, which was then probed for phosphotyrosine content with phosphotyrosine-specific antibody.

Specifically, H928 cells (2×10⁵) in 100 μL medium were added to each well in a flat-bottom 24-well culture plate and cultured overnight at 37° C. in 5% CO₂. After the supernatants were removed, the cells were serum-starved for 24

hours. A medium containing a test compound was added into each well and the cell culture was incubated for 30 minutes before it was stimulated by recombinant VEGF-C for 15 minutes. After the supernatants were removed, 100 μ l of a lysis buffer were added into each well to lyse the cells and solubilize the VEGFR3. The lysis buffer included 150 mM NaCl containing 50 mM Hepes (Genentech media prep), 0.5% Triton-X 100 (Genentech media prep), 0.01% thimerosol, 30 kIU/ml aprotinin (ICN Biochemicals, Aurora, Ohio), 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSE; ICN Biochemicals), and 2 mM sodium orthovanadate. The plate was then put on a plate shaker (Bellco Instruments Vineland, N.J.) and the substance in each well of the plate underwent mixing for 60 minutes at room temperature. While the cells were being solubilized, an ELISA microtiter plate (Nunc Maxisorp, Inter Med, Denmark) coated overnight at 4° C. with the affinity-purified polyclonal anti-VEGFR 3 (2.5 μ g/ml in phosphate buffered saline (PBS), 100 μ l/well) were decanted, tamped on a paper towel, and blocked with 150 μ l/well block buffer (PBS containing 0.5% BSA and 0.01% thimerosol) for 60 minutes at room temperature with gentle agitation. The anti-VEGFR 3-coated plate was subsequently washed twice with a wash buffer (PBS containing 0.05% Tween 20 and 0.01% thimerosol). The lysate containing solubilized VEGFR 3 from the cell-culture microtiter well were transferred (85 μ l/well) to the anti-VEGFR 3-coated ELISA plate and incubated for 2 hours at room temperature with gentle agitation. The unbound receptors were removed by washing with a wash buffer. 100 μ l of biotinylated 4G10 (antiphosphotyrosine) diluted to 0.2 μ g/ml in dilution buffer (PBS containing 0.5% BSA, 0.05% Tween 20, 5 mM EDTA, and 0.01% thimerosol) were added into each well. After incubation for 2 hours at room temperature, the plate were washed and 100 μ l HRP-conjugated streptavidin (Zymed Laboratories, S. San Francisco, Calif.) diluted 1:2000 in dilution buffer will be further added. After the free avidin conjugate were washed away, 100 μ l freshly prepared substrate solution (tetramethyl benzidine, TMB) was added to each well. The reaction was allowed to proceed for 10 minutes and the color development was stopped by the addition of 100 μ l/well 1.0 M H₃PO₄. The absorbance at 450 nm and the absorbance at a reference wavelength of 650 nm ($A_{450/650}$) were measured using an ELISA reader.

The inhibition efficacy of each test compound is expressed as an inhibition percentage calculated according to the following formula: $1 - [(C-A)/(B-A)]$. In this formula, A is the basal amount of phosphotyrosine detected in a blank control, B is the amount of phosphotyrosine detected with VEGF-C only, and C is the amount of phosphotyrosine detected with a test compound and VEGF-C.

Among the 186 compounds already synthesized, 118 compounds (i.e., compounds 1-22, 24-30, 32, 34-39, 41-50, 52-122, and 186) were tested. Unexpectedly, Compound 2, at concentration of 1 μ M, showed an inhibition percentage of about 65%; Compounds 26, 57-58, 60-61, 66-68, 70, 72-77, 79-80, 82, 86, 88, 90, 93-96, 98-99, 102-103, 105-108, 110-112, 115, 120, and 186 each showed substantially the same inhibition percentage as Compound 2; and Compounds 11, 56, 59, 62, 64-65, 81, 83-85, 87, 89, 91, 100, 113-114, 117, 119, and 121 each showed an even higher inhibition percentage than Compound 2.

EXAMPLE 188

In vivo Assay on Tumor Growth Inhibition

Compounds were tested for their efficacy in inhibiting tumor growth on murine tumor xenografts.

Murine 4T1 breast cancer cells (purchased from the American Type Culture Collection) were cultured to sub confluence in RPMI medium supplemented with 10% fetal bovine serum (GIBCO Invitrogen Corp.) at 37° C., 90% humidity and 5% CO₂. The 4T1^{LUC+} cells were established by the stable transfection of the firefly luciferase gene (pGL3-control, Promega Corporation) to 4T1 cells using LipofectAMINE PLUS Reagent (Life Technologies, Inc., Grand Island, N.Y.) for quantitative assessment of tumor burden in visceral organs. pcDNA3 vector (Invitrogen Co., Carlsbad, Calif.) was cotransfected for the selection by G418 (Sigma). The resulting 4T1^{LUC+} colonies were isolated and cultured independently and the best expressing lines were identified based on the level of bioluminescent activity in the presence of luciferin in living cells. Highly bioluminescent clone was selected for further studies.

Next, 4T1^{LUC+} cells were orthotopically implanted into the right inguinal mammary fat pads of 6 to 8-week old female BALB/c mice (1×10^5 cells in 100 μ l PBS/mouse). After 14 days of tumor cell implantation, a single dose of 50 mg/kg body weight of a test compound or vehicle was administered intraperitoneally once daily.

The length (i.e., the biggest diameter) and width (i.e., the smallest diameter) of the tumor was measured every 3.5 days by using a Vernier caliper. The tumor volume was then calculated as follows: $\text{volume} = A \times B^2 \times 0.52$, where A is the length of the tumor and B is the width of the tumor.

Compounds 2, 56, and 91 (i.e., the acid form of Compound 56, denoted as 56-A in FIG. 1) were tested. Sorafenib (Nexavar®) and sunitinib (Sutent®), two commercial anti-cancer drugs, were used as reference compounds. Unexpectedly, Compound 56 (denoted as 56-E) inhibited tumor growth almost as effectively as Sutent and Sorafenib, as shown in FIG. 1. Also unexpectedly, mice treated with Compound 56 showed a higher survival rate than those treated with Sorafenib.

EXAMPLE 189

In vivo Assay on Inhibiting Spontaneous Metastasis

To investigate the effect of test compounds on distant spontaneous metastasis generated by the tumor cells, 4T1^{LUC+} cells obtained by the method described in Example 188 were implanted into the right inguinal mammary fat pads of 6-week old BALB/c mice (1×10^5 cells in 100 μ l PBS/mouse). After 14 days of tumor cell implantation, a single dose of 50 mg/kg body weight of a test compound or vehicle was administered intraperitoneally once daily. Compounds 2, 56, and 91 were used in this assay. Sorafenib (Nexavar®) and sunitinib (Sutent®) were also used as reference compounds.

A total of 36 mice, six for each of the six groups (i.e., 5 groups treated with test compounds and 1 vehicle group), were imaged once weekly for a period of 6 weeks after tumor cell implantation via bioluminescence imaging.

In vivo bioluminescence imaging was conducted on a cryogenically cooled IVIS™ system (Xenogen Corp., Alameda, Calif.) coupled to a data-acquisition PC running Living Image version 3.1 software (Xenogen Corp.). Before imaging, animals were anesthetized in a plastic chamber filled with 2% isoflurane/air mixture and 150 mg/mL of luciferin (potassium salt, Xenogen Corp.) and normal saline was injected (i.p.) into each mouse at a dose of 150 mg/kg body weight. This dose and route of administration has been previously shown to be optimal for studies in rodents when images were acquired between 10 and 20 minutes post-luciferin administration (Contag C H et al. 1997 *Photochem Photobiol.*;

66:523-531). During image acquisition, isoflurane anesthesia was maintained using a nose cone delivery system and animal body temperature was regulated using a digitally thermostated bed integrated within the IVIS™ system (Xenogen Corp., Alameda, Calif.). A gray scale body surface image was collected in the chamber under dim illumination, followed by acquisition and overlay of the pseudocolor image representing the spatial distribution of detected photon counts emerging from active luciferase within the animal. An integration time of 1 minute was used for luminescent image acquisition.

The average of the in vivo bioluminescence intensities measured on the 14th day post tumor cell implantation but before treatment with test compounds served as a baseline, corresponding to the metastatic tumor burden of the vehicle group, as shown in FIG. 2.

Unexpectedly, at the end of the fourth week after compound treatment (i.e., the sixth week after tumor cell implantation), the groups administered with Compound 2 (denoted as “Comp 2” in FIG. 2) and Compound 91 (denoted as “56-A”) exhibited significant lower luminescent signal intensity as compared with the vehicle group while the group treated with Compound 56 (denoted as “56-E”) did not exhibit any detectable luminescent signal. See FIG. 2.

The observation indicates that Compounds 2, 56, and 91 are unexpectedly comparable or superior to the commercial drugs such as Sorafenib (Nexavar®) and sunitinib (Sutent®) on the inhibition of the spontaneous metastasis generated by the tumor cells.

EXAMPLE 190

Effects on Tumor Recurrence and Survival Rate

4T1^{LUC+} cells obtained by the method described in Example 188 were implanted into the right inguinal mammary fat pads of 6 to 8-week old female BALB/c mice (1×10⁵ cells in 100 μL PBS/mouse). After 14 days of tumor cell implantation, a single dose of 50 mg/kg body weight of a test compound or vehicle (PBS) was administered intraperitoneally once daily for three weeks. Compounds 2, 56, and 91 were tested in this assay. Sorafenib (Nexavar®) and sunitinib (Sutent®) were also used as reference compounds.

At the end of three-week treatment, the orthotopically grown tumors were surgically removed from the six groups of mice (i.e., 5 groups each treated with a test compound and 1 vehicle group). Then each of the six groups (i.e., 5 groups each treated with a test compound and 1 vehicle group) were divided into two subgroups, one with no further drug treatment (denoted as “stop treatment” in FIG. 3) and the other with continued drug treatment for 35 days (denoted as the “sustain treatment” in FIG. 3).

Bioluminescent data were collected in a manner similar to that described in Example 189 above at the end of day 35 after tumor resection.

Unexpectedly, as showed in the FIG. 3, the groups administered with Compound 2 (denoted as “Comp 2” in FIG. 3), Compound 56 (denoted as “56-E”), and Compound 91 (denoted as “56-A”) after tumor resection all exhibited lower luminescent signal intensity as compared with the corresponding group without continuous treatment. This observation indicates that these compounds decrease the chance of tumor recurrence.

In addition, Compound 56 reduced tumor recurrence to a degree comparable to that of sunitinib (Sutent®).

Also unexpectedly, as indicated by the survival curves in FIG. 4, Compounds 2, 56, and 91 increased the overall survival life span of the treated mice as compared with those in

the vehicle group. In addition, the “sustain treatment” subgroup of each treated group exhibited a higher survival rate than the “stop treatment” subgroup.

EXAMPLE 191

Effects on Tumor Self-Seeding

Unlabeled parental 4T1 cells were implanted into a mammary gland of 6 to 8-week old female BALB/c mice (1×10⁵ cells in 100 μL PBS/mouse). After 14 days of tumor cell implantation, a single dose of 50 mg/kg body weight of a test compound or vehicle (PBS) was administered orally once daily for 2 days. Compound 56 was tested in this assay. Sunitinib (Sutent®) was used as a reference compound. Then 4T1^{LUC+} cells (1×10⁵ cells in 100 μL PBS/mouse) were injected into the circulatory system of the mice by intracardiac injection. The mice were then administered orally with a single dose of 50 mg/kg body weight of a test compound or vehicle (PBS) once daily for 2 days.

Bioluminescent data were collected in a manner similar to that described in Example 189 above.

Unexpectedly, as shown in FIGS. 5A and 5B, the mice treated with Compound 56 (denoted as “56-E”) and Sutent exhibited much weaker bioluminescence from the thoracic cavity at day 7 post the second 2-day drug treatment as well as much weaker bioluminescence from the abdominal cavity at day 14 post the second 2-day drug treatment as compared with the vehicle group. Even more surprisingly, the mice treated with Compound 56 (denoted as “56-E”) exhibited weaker bioluminescence from the abdominal cavity at day 14 post the second 2-day drug treatment as compared with the Sutent-treated group. These observations indicate that Compound 56 exhibited comparable or even superior ability in inhibiting tumor self-seeding to that of Sutent.


OTHER EMBODIMENTS

All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.

What is claimed is:

1. A compound of formula (I):



(I)

wherein

X₁ is N;

X₂ is C;

111

X₃ is N;R₁ is alkyl or cycloalkyl;R₃ is deleted




R₂ is substituted and unsubstituted benzimidazol-4-yl, substituted and unsubstituted dihydrobenzimidazol-4-yl or substituted and unsubstituted indazol-6-yl;

R₄, R₆, and R₇ are H; and

R₅ is COOR_d wherein R_d is H or alkyl, or a salt, a prodrug or a solvate thereof.

2. The compound of claim 1, wherein R₂ is substituted and unsubstituted indazol-6-yl.





3. The compound of claim 2, wherein the compound is one of the compounds as follows:



112

-continued




Compound 27



65 4. The compound of claim 1, wherein R₂ is substituted and unsubstituted benzimidazol-4-yl, or dihydrobenzimidazol-4-yl.

113


5. The compound of claim 4, wherein the compound is one of the compounds as follows:




114

-continued


Compound 64




Compound 65



Compound 81




Compound 83



115
-continued

Compound 84




5

10

15

Compound 85




20

25

30

Compound 87




35

40

45

Compound 89



50


55

60


65

116
-continued


Compound 91




Compound 100



Compound 113




117
-continued




Compound 114

118
-continued



Compound 121

Compound 119



25

30

35

40

6. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1.

7. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 2.

8. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 4.

* * * * *